Novartis | Passività Correnti



Current Liabilities Cambiamento Data
AbbVie USD 38.75B 4.31B 2024-12
Alcon AG USD 2.25B 32M 2025-03
Almirall EUR 353.42M 79.41M 2024-12
Amgen USD 23.01B 91M 2025-03
AstraZeneca USD 29.13B 1.26B 2025-03
Autolus Therapeutics Ltd 66.61M 5.87M 2025-03
Bayer EUR 27.96B 993M 2025-03
Biogen USD 5.3B 231.4M 2025-03
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Eli Lilly USD 30.07B 1.69B 2025-03
Fresenius EUR 8.33B 2.24B 2025-03
Fresenius Medical Care EUR 5.45B 213.2M 2025-03
Galapagos EUR 437.04M 101.96M 2025-03
Genmab DKK 756M 4.55B 2025-03
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 20.83B 866M 2025-03
GRIFOLS EUR 2.17B 14.07M 2025-03
Hikma Pharmaceutical USD 1.38B 41M 2024-06
J&J USD 56.9B 6.58B 2025-03
Lonza CHF 3.58B 970M 2024-12
Merck EUR 11.29B 831M 2024-12
Merck USD 25.17B 3.25B 2025-03
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 236.12B 27.76B 2025-03
Orion EUR 286.2M 12.8M 2025-03
Pfizer USD 36.45B 6.54B 2025-03
Philips EUR 6.76B 1.39B 2025-03
Recordati EUR 986M 79.3M 2025-03
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 32.22B 3.06B 2025-03
UCB EUR 3.53B 731M 2024-12



Novartis Passività Correnti - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - May 2025.